1 year ago: Dec 22, 2022 is when NICE restarted the review process.
Ex,
It’s better to get your evidence and strategy right first time.
Interesting read here IMO.
Market access planning with Organon A NICE Advice case study
In this case study, we speak with Sarah Brown, Organon’s access lead for the UK and Ireland. Organon is a global healthcare company with a focus on women’s health. Sarah is leading on the product launch for a new obstetric product. Sarah explains how NICE Advice, NICE's refreshed support service for the life sciences industry, brought together the best people to help inform Organon’s market access planning for this technology.
Unrivalled expertise
While Sarah has a wealth of global experience launching pharmaceutical products, she had limited knowledge of the UK healthtech market.
“I was keen to soak up as much information as possible,” Sarah reveals. “I looked to partner with the most appropriate organisation to achieve my goal.”
From her background in pharmaceuticals, Sarah was already familiar with NICE’s work and the valuable support provided. “NICE is such a trusted body,” she says. “By partnering with them, I knew I could have complete confidence in the end-to-end process.”
A tailored approach
Our NICE Advice team worked with Sarah to facilitate a health system engagement meeting with NHS stakeholders. Our engagement meetings are designed to generate expert stakeholder insights that are often used to help shape a company’s market access strategy. Tailored to your specific requirements and budget, relevant stakeholders are brought together in one meeting. They can help you to:
understand the changing healthcare landscape identify the right route to NHS access explore and test your value proposition.
“NICE Advice crafted a cross functional team of experts,” Sarah enthuses. “From NHS Supply Chain colleagues to clinicians working within the therapy area, having NICE’s support setting everything up took the pressure away.”
Setting the standard
As the NHS in England’s health technology assessment body, we help set the evidence standards companies need to meet to gain nationwide market entry. For Sarah, a key takeaway from the meeting was the importance of real-world evidence. “It highlighted the UK market expectations when it comes to healthtech,” she states. “We were struck by the importance placed on real-world data generation from within an NHS setting.”
As a result of this feedback, Organon is currently working with Health Innovation North East and North Cumbria to establish real-world evidence data collection sites within local NHS trusts.
Recognised globally
Sarah’s experience of working with NICE Advice has helped shape Organon’s decision-making process in terms of seeking a NICE evaluation for their product. The company is now considering this route. “Other countries look to NICE,” she asserts. “A positive recommendation from NICE sends a powerful signal to global markets beyond the UK.”
Valuable NHS connections
For other healthtech developers who are exploring how best to introduce their products to the NHS, Sarah explains how NICE’s close connections and established partnerships with senior NHS stakeholders is beneficial to companies like hers.
“The support you need is right here, closely connected to the NHS," she asserts. "People at NICE want to help you. They are passionate about bringing the latest innovations to market.”
NICE Advice
As the NHS in England’s health technology assessment body, our NICE Advice service is uniquely placed to help life science companies demonstrate product value, optimise your access strategy, and achieve nationwide adoption of the best treatments and care. Receive accurate, reliable and actionable advice, education and insights, direct from NICE.
NICE Advice can help you to:
-Increase your knowledge of NICE, our health technology assessment methods and processes, regulatory requirements, and NHS decision-makers’ perspectives.
-Understand the most suitable route to market for your product.
-Identify what matters most to patients, health and care professionals and the wider system.
-Establish a clear, purposeful value proposition outlining the value your technology brings to the UK health and care system.
-Gain expert feedback and actionable advice on your evidence generation plans or health economic model, to help demonstrate the impact of your product to NHS decision makers.
-Engage early with the healthcare system, establish key contacts and gain vital insights, advancing your path to adoption and uptake.
Our aim is to drive innovation into the hands of health and care professionals to enable best practice.
